IT Type
Bispecific IT
Description
A novel bispecific single-chain fusion protein DT2219, consisting of the catalytic and translocation domain of diphtheria toxin (DT (390)), fused to two repetitive sFv subunits that recognize CD19 and CD22. Compared with monomers or bivalent immunotoxins made with anti-CD19 and anti-CD22 sFv alone, DT2219 has greater anticancer activity. DT2219 is more reactive in identifying B-cell malignancies, has greater lethality, and requires fewer toxins, so it is necessary to further study its use as a new drug for the treatment of B leukemia / lymphoma.
Indication
Refractory B-cell malignancies; B-cell Leukemia/Lymphoma
Classification
Immuntoxin; biobetter
Construction
scFv19/22-DT390
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop our ADCC/CDC-enhanced antibodies or immutoxins. For commercial partners interested in our therapeutic biobetter product, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD19;CD22
Full Name
CD19 Molecule; CD22 Molecule
Background
This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein.
Alternative Names
CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; B-Lymphocyte Antigen CD19; CVID3; B4; CD22 Molecule; CD22 Antigen; Sialic Acid-Binding Ig-Like Lectin 2; B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2;
Antibody Clone
RFB4; HD37
Antibody Type
scFv
Antibody Indication
Refractory B-cell malignancies; B-cell Leukemia/Lymphoma
Toxic Moiety
DT390
Organism
Corynebacterium
Family
Diphtheria toxin
Molecular Mass
35.64kD
Toxic MOA
Diphtheria toxin (DT) is one of the most extensively studied bacterial toxins with intracellular action. The first 390 amino acid residues of DT (DT390) contain the catalytic domain or A chain of DT that inhibits protein synthesis by ADP ribosylation of elongation factor 2 (EF-2) and the translocation domain that translocates the catalytic domain to the cytosol by interaction with cytosolic Hsp90 and thioredoxin reductase.
Refractory B-cell malignancies; B-cell Leukemia/Lymphoma
